Akitaka Makiyama
Overview
Explore the profile of Akitaka Makiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasufuku I, Takai K, Takaha R, Fujibayashi S, Chikaishi W, Makiyama A, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
52(1):10-14.
PMID: 39957216
Conversion surgery for gastric cancer is defined as surgery for tumors with distant metastases that are technically or oncologically unresectable at diagnosis, with the aim of achieving R0 resection after...
2.
Taniguchi H, Uehara K, Ishikawa T, Okochi O, Akazawa N, Okuda H, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941768
Background/objectives: BRAF mutations occur in 5-10% of metastatic colorectal cancer (mCRC) cases, but their implications for prognosis and optimal treatment remain unclear. Methods: This multicenter, prospective observational study analyzed 377...
3.
Ando K, Satake H, Shimokawa M, Yasui H, Negoro Y, Kinjo T, et al.
Int J Clin Oncol
. 2025 Feb;
30(3):514-523.
PMID: 39891883
Background: FOLFOXIRI plus bevacizumab (BEV) is an option for first-line treatment of metastatic colorectal cancer (mCRC). However, there is no consensus on the optimal treatment strategy when disease progresses. The...
4.
Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, et al.
Gastric Cancer
. 2024 Dec;
28(2):301-308.
PMID: 39738793
Background: Microsatellite instability (MSI)-high tumors represent a distinct, small-fraction subtype in esophagogastric junction cancer or gastric cancer (GC), yet their clinical significance remains poorly understood. This study aimed to investigate...
5.
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al.
Gastric Cancer
. 2024 Nov;
28(1):62.
PMID: 39607631
No abstract available.
6.
Miyashita K, Shioi S, Kajitani T, Koi Y, Shimokawa M, Makiyama A, et al.
Sci Rep
. 2024 Nov;
14(1):27257.
PMID: 39516234
Microsatellite instability (MSI) is now widely used as an indispensable biomarker. However, the relationship between MSI-H (high) and defective DNA mismatch repair (MMR) is not as straightforward as has been...
7.
Hayashi H, Yasufuku I, Sato Y, Fujibayashi S, Chikaishi W, Endo M, et al.
Oncol Lett
. 2024 Nov;
29(1):20.
PMID: 39492934
Studies have associated neutrophil-to-lymphocyte ratio (NLR) with overall survival (OS) and progression-free survival (PFS) in patients with gastric cancer (GC). The present study aimed to examine the relationship between dynamic...
8.
Araki T, Kawahira M, Shimokawa M, Otsuka T, Hayashi K, Sonoda Y, et al.
Oncology
. 2024 Oct;
:1-11.
PMID: 39427640
Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate...
9.
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, et al.
Gastric Cancer
. 2024 Oct;
28(1):51-61.
PMID: 39387986
Background: Trastuzumab-deruxtecan (T-DXd) was approved for the treatment of HER2-positive patients with advanced gastric cancer in Japan based on the results of the DESTINY-Gastric01 trial. This study aimed to collect...
10.
Shibuki T, Otsuka T, Shimokawa M, Nakazawa J, Arima S, Fukahori M, et al.
Sci Rep
. 2024 Jul;
14(1):16906.
PMID: 39043707
This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab-paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective...